CLINICAL TRIALS PROFILE FOR VEKLURY
✉ Email this page to a colleague
All Clinical Trials for veklury
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04784559 ↗ | Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection | Recruiting | PharmaMar | Phase 3 | 2021-06-04 | Treatment of patients hospitalised for management of moderate COVID-19 infection |
| NCT04832880 ↗ | Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial) | Not yet recruiting | ASST Fatebenefratelli Sacco | Phase 3 | 2021-04-06 | Background: In the current worldwide medical emergency, a rapid identification of effective therapeutic strategy is crucial. So far, therapy with dexamethasone, remdesivir and baricitinib have been associated with evidence of impact on the clinical impact on COVID-19, but the effect of baricitinib and remdesivir in combination with dexamethasone. The AAMMURAVID trial is endorced and supported by the Italian Regulatory agency (AIFA-Agenzia Italiana del Farmaco) |
| NCT04853901 ↗ | Remdesivir Efficacy In Management Of COVID-19 Patients | Completed | Ain Shams University | Phase 3 | 2020-07-27 | The study is open label randomized interventional phase 3 clinical trial. Patients with confirmed Covid-19 cases who was hospitalized in Two university isolation hospitals (Ain Shams University and Assiut University ) assigned hospitals for isolation. |
| NCT04871633 ↗ | Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore | Completed | King Edward Medical University | N/A | 2020-08-01 | Currently, several drugs including Remdesivir, hydroxychloroquine, chloroquine, ritonavir+lopinavir, Tocilizumab, Arbidol and interferon are under randomised controlled trials (RCTs) for efficacy and/or safety evaluations in patients with COVID-19 in different countries. Remdesivir (GS-5734) is among these investigational drugs and some studies reported promising results. Remdesivir is a nucleotide analogue intravenous pro-drug developed by Gilead Sciences, an American biopharmaceutical company, for treatment of Ebola virus during the 2014 Ebola outbreak in Western Africa. Remdesivir shows broad-spectrum antiviral activity against many RNA viruses including SARS-CoV-2 through blocking RNA polymerase thereby terminating RNA transcription. Remdesivir was among the first treatments used in China as the outbreak emerges and it has been reported as potential treatment options for COVID-19 in the USA, China and Italy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for veklury
Condition Name
Clinical Trial Locations for veklury
Clinical Trial Progress for veklury
Clinical Trial Phase
Clinical Trial Sponsors for veklury
Sponsor Name
